Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631670 | 0.92 | CYP3A4 (0.49) | CACNA1GOPRM1KCNH2SIGMAR1CYP3A4 | |
| SCHEMBL19631637 | 0.88 | PRKAA2 (0.48) | PRKAA2CYP3A4CYP2C9KMT2A | |
| SCHEMBL19631591 | 0.87 | OPRM1 (0.45) | CACNA1GOPRM1OPRD1KCNH2PRKAA2 | |
| SCHEMBL19631725 | 0.84 | KDM4E (0.47) | CACNA1GOPRM1OPRD1KCNH2PRKAA2 | |
| SCHEMBL19631642 | 0.79 | CTSK (0.37) | CYP3A4CYP2C9KDM4E | |
| SCHEMBL19631554 | 0.79 | CYP3A4 (0.45) | OPRM1SIGMAR1CYP3A4CYP2C9KDM4E | |
| SCHEMBL19631594 | 0.79 | CYP3A4 (0.45) | OPRM1SIGMAR1CYP3A4CYP2C9KDM4E | |
| SCHEMBL21233668 | 0.79 | CYP3A4 (0.45) | OPRM1SIGMAR1CYP3A4CYP2C9KDM4E | |
| SCHEMBL22169524 | 0.79 | CYP3A4 (0.45) | OPRM1SIGMAR1CYP3A4CYP2C9KDM4E | |
| SCHEMBL19631701 | 0.79 | CYP3A4 (0.45) | OPRM1KCNH2SIGMAR1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-10-20 | — | — | US | disclosed |
| EP-3458450-B1 | TETRAHYDROPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2020-07-01 | — | — | EP | disclosed |
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-08-08 | — | — | US | disclosed |
| WO-2017198339-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241544-A1 | TETRAHYDROPYRAN AND THIOPYRAN DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | CACNA1G 227/4885OPRM1 4/4885OPRD1 1/4885 |
| US-10807970-B2 | Tetrahydropyran and thiopyran derivatives having multimodal activity against pain | OPRD1, SIGMAR1, OPRK1 | CACNA1G 227/4885OPRM1 4/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.